Dynamic Technology Lab Private Ltd Buys New Holdings in DexCom, Inc. (NASDAQ:DXCM)

Dynamic Technology Lab Private Ltd purchased a new position in DexCom, Inc. (NASDAQ:DXCM) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 14,331 shares of the medical device company’s stock, valued at approximately $961,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of DexCom during the second quarter valued at about $25,000. Sachetta LLC lifted its position in DexCom by 255.2% in the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after acquiring an additional 171 shares in the last quarter. Riverview Trust Co boosted its stake in DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after purchasing an additional 232 shares during the last quarter. DT Investment Partners LLC increased its holdings in DexCom by 492.2% during the 2nd quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock worth $43,000 after purchasing an additional 315 shares in the last quarter. Finally, ORG Partners LLC raised its stake in shares of DexCom by 1,992.0% in the second quarter. ORG Partners LLC now owns 523 shares of the medical device company’s stock worth $59,000 after purchasing an additional 498 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Activity

In other news, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares in the company, valued at approximately $18,318,872.25. This trade represents a 0.28 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Sadie Stern sold 426 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the sale, the executive vice president now directly owns 75,451 shares in the company, valued at $5,217,436.65. This trade represents a 0.56 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 5,431 shares of company stock worth $399,319. 0.30% of the stock is owned by corporate insiders.

DexCom Stock Up 0.2 %

DexCom stock opened at $78.10 on Thursday. The firm has a 50 day simple moving average of $71.11 and a 200 day simple moving average of $88.51. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The firm has a market capitalization of $30.51 billion, a price-to-earnings ratio of 46.77, a P/E/G ratio of 2.38 and a beta of 1.17.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. Royal Bank of Canada cut their target price on DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Sanford C. Bernstein increased their price objective on shares of DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. Robert W. Baird boosted their target price on DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a research note on Monday, August 5th. JPMorgan Chase & Co. increased their price target on DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Finally, StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Seven analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $104.59.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.